Edition:
United Kingdom

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

4.40USD
8:59pm GMT
Change (% chg)

$-0.20 (-4.35%)
Prev Close
$4.60
Open
$4.55
Day's High
$4.55
Day's Low
$4.25
Volume
93,883
Avg. Vol
91,054
52-wk High
$6.45
52-wk Low
$2.58

Select another date:

Wed, Dec 6 2017

BRIEF-Adamis Pharmaceuticals Subsidiary Develops Compound To Manage Ulcers In Horses

* US COMPOUNDING, A SUBSIDIARY OF ADAMIS PHARMACEUTICALS, DEVELOPS A UNIQUE COMPOUND TO MANAGE ULCERS IN HORSES Source text for Eikon: Further company coverage:

BRIEF-Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA

* ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi

* ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI

Adamis wins U.S. approval to sell EpiPen rival, shares soar

Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

UPDATE 2-Adamis wins U.S. approval to sell EpiPen rival, shares soar

June 15 Adamis Pharmaceuticals Corp said on Thursday it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan NV's widely used EpiPen, sending its shares up more than 50 percent.

Adamis gets U.S. approval to sell EpiPen rival, shares soar

June 15 Adamis Pharmaceuticals on Thursday said it received U.S. approval for its emergency epinephrine syringes to treat severe allergic reactions that would compete with Mylan's widely used EpiPen, sending its shares up 50 percent.

BRIEF-Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe

* Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe

Select another date: